

Atoltivimab + maftivimab + odesivimab

Essential medicine status

General description

Medicine type

Biological agent

EML status history

First added in 2023 ([TRS 1049](#)) for [Ebola virus disease](#)

Wikipedia

[Atoltivimab + maftivimab + odesivimab](#)

DrugBank

[Atoltivimab](#),

[Maftivimab](#),

[Odesivimab](#)

Recommendations

Section

Medicines for Ebola virus disease

- Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial

Indications

[Ebola virus disease](#)